{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:01:11Z","timestamp":1789923671862,"version":"4.0.1"},"reference-count":24,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Menopause International"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p>Postmenopausal estrogen deficiency can lead to symptoms of urogenital atrophy. Individuals with urogenital atrophy have symptoms that include vaginal dryness, vaginal and vulval irritation, vaginal soreness, pain and burning during urination (dysuria), increased vaginal discharge, vaginal odour, vaginal infections, recurrent urinary tract infections, pain associated with sexual activity (dyspareunia) and vaginal bleeding associated with sexual activity. Despite the frequency and effects of vaginal atrophy symptoms, they are often under-reported and, consequently, under-treated. Therefore, care of a menopausal woman should include a physical assessment of vaginal atrophy and a dialogue between the physician and the patient that explores existing symptoms and their effect on vulvovaginal health, sexuality and quality-of-life issues. The development of the ultra-low-dose 10-\u00b5g estradiol vaginal tablets is in line with the requirements of regulatory agencies and women's health societies regarding the use of the lowest effective hormonal dose. Because of its effectiveness and safety profiles, in addition to its minimal systemic absorption, the 10-\u00b5g estradiol vaginal tablet can offer greater reassurance to health-care providers and postmenopausal women with an annual estradiol administration of only 1.14 mg.<\/jats:p>","DOI":"10.1258\/mi.2012.011120","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T19:28:06Z","timestamp":1330975686000},"page":"15-19","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of postmenopausal vaginal atrophy with 10-\u00b5g estradiol vaginal tablets"],"prefix":"10.1080","volume":"18","author":[{"given":"Nick","family":"Panay","sequence":"first","affiliation":[{"name":"Queen Charlotte's & Chelsea and Chelsea & Westminster Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Maamari","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,3,5]]},"reference":[{"key":"bibr-MI-11-120C1","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2010.522875"},{"key":"bibr-MI-11-120C2","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31805170eb"},{"key":"bibr-MI-11-120C3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01198.x"},{"key":"bibr-MI-11-120C4","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1097\/01.AOG.0000129237.93777.1a","volume":"104","author":"American College of Obstetricians and Gynecologists","year":"2004","journal-title":"Obstet Gynecol"},{"key":"bibr-MI-11-120C5","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2009.1384"},{"key":"bibr-MI-11-120C6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00818.x"},{"key":"bibr-MI-11-120C7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00448.x"},{"key":"bibr-MI-11-120C8","first-page":"S85","volume":"104","author":"American College of Obstetricians and Gynecologists","year":"2004","journal-title":"Obstet Gynecol"},{"key":"bibr-MI-11-120C9","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181d0f6b9"},{"key":"bibr-MI-11-120C10","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms \u2013 prescribing information for health care providers and patient labeling [updated February 2004]. See http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/UCM135336.pdf (last checked 30 November 2011)"},{"key":"bibr-MI-11-120C11","doi-asserted-by":"publisher","DOI":"10.1080\/13697130801983921"},{"key":"bibr-MI-11-120C12","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2007.05.003"},{"key":"bibr-MI-11-120C13","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0765"},{"key":"bibr-MI-11-120C14","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2010.483297"},{"key":"bibr-MI-11-120C15","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31818aa7c3"},{"key":"bibr-MI-11-120C16","first-page":"CD000402","author":"Furness S","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr-MI-11-120C17","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f386bb"},{"key":"bibr-MI-11-120C18","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2010.481058"},{"key":"bibr-MI-11-120C19","unstructured":"Committee for Medical Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. London, UK, 2005 [updated 13 October 2005]. See http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003348.pdf (last checked 30 November 2011)"},{"key":"bibr-MI-11-120C20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00051699"},{"key":"bibr-MI-11-120C21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rigp.2005.01.001"},{"key":"bibr-MI-11-120C22","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms \u2013 recommendations for clinical evaluation [updated January 2003]. See http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/UCM135338.pdf (last checked 30 November 2011)"},{"key":"bibr-MI-11-120C23","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31817b076a"},{"key":"bibr-MI-11-120C24","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2005.02.019"}],"container-title":["Menopause International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/mi.2012.011120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1258\/mi.2012.011120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/mi.2012.011120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:30:14Z","timestamp":1766518214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/mi.2012.011120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1258\/mi.2012.011120"],"URL":"https:\/\/doi.org\/10.1258\/mi.2012.011120","relation":{},"ISSN":["1754-0453"],"issn-type":[{"value":"1754-0453","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}